2 research outputs found
Combretastatin A‑4 Analogue: A Dual-Targeting and Tubulin Inhibitor Containing Antitumor Pt(IV) Moiety with a Unique Mode of Action
Three
new PtÂ(IV) complexes comprising a combretastatin A-4 analogue
were designed and synthesized. The resulting antitumor PtÂ(IV) complexes
could significantly improve the antiproliferative activity and overcome
the drug resistance of cisplatin in vitro. Interestingly, these novel
compounds not only can carry the DNA binding PtÂ(II) warhead into the
cancer cells but also have a small molecule fragment that can inhibit
tubulin polymerization. Among them, complex <b>13</b>, which
was attached to an inhibitor of tubulin at one axial position of PtÂ(IV)
octahedral coordination sphere, could effectively enter cancer cells,
arrest the cell cycle in HepG-2 cancer cells at G2/M phases, and induce
activation of caspases triggering apoptotic signaling via the mitochondrial-dependent
apoptosis pathways. Moreover, complex <b>13</b> has the ability
to effectively inhibit the tumor growth in the HepG-2 xenograft model
without causing significant loss of animal body weight in comparison
with cisplatin
A Unique Chemo-photodynamic Antitumor Approach to Suppress Hypoxia via Ultrathin Graphitic Carbon Nitride Nanosheets Supported a Platinum(IV) Prodrug
Tumor hypoxia severely restrains the efficiency of irreversible
O2-consumption photodynamic therapy. The deep hypoxia induced
by photodynamic therapy can promote the level of hypoxia inducible
factor 1α that participates in many tumor processes and eventually
lead to poor therapeutic outcomes. Herein, a chemo-photodynamic antitumor
strategy based on ultrathin graphitic carbon nitride nanosheets loaded
with a hypoxia-targeting platinum(IV) prodrug is reported. Under low-intensity
visible light irradiation, such integrated nanosheets effectively
generate reactive oxygen species together with DNA binding platinum
species to achieve enhanced antiproliferation efficacy by downregulating
HIF-1α under hypoxic conditions